Is nonalcoholic fatty liver disease an endogenous alcoholic fatty liver disease? - A mechanistic hypothesis

Medical Hypotheses

Volumn 85, Issue 2, 2015, Pages 148-152

  de Medeiros, Ivanildo Coutinho ^a   de Lima, Josivan Gomes ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACETALDEHYDE; ALCOHOL; ALCOHOL DEHYDROGENASE; FATTY ACID ESTER;

ALCOHOL BLOOD LEVEL; ALCOHOL METABOLISM; ALCOHOLIC FATTY LIVER; ARTICLE; BACTERIAL OVERGROWTH; CATABOLISM; DISEASE COURSE; FIRST PASS EFFECT; GENETIC CODE; HUMAN; INTESTINE FLORA; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; STOMACH JUICE; UPREGULATION; BIOLOGICAL MODEL; METABOLISM; MICROBIOLOGY; PHYSIOLOGY;

ACETALDEHYDE; ETHANOL; FATTY LIVER, ALCOHOLIC; GASTROINTESTINAL MICROBIOME; HUMANS; MODELS, BIOLOGICAL; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84944358185     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2015.04.021     Document Type: Article

References (88)

1. Polyzos SA, Kountouras J, Zavos C, Deretzi G. Nonalcoholic fatty liver disease: multimodal treatment options for a pathogenetically multiple-hit disease. J Clin Gastroenterol 2012;46:272-84. http://dx.doi.org/10.1097/MCG.0b013e31824587-0
2. Allard JP. Other disease associations with non-alcoholic fatty liver disease (NAFLD). Best Pract Res Clin Gastroenterol 2002;16:783-95. http://dx.doi.org/10.1053/bega.2002.0330.
3. Syn WK, Teaberry V, Choi SS, Diehl AM. Similarities and differences in the pathogenesis of alcoholic and nonalcoholic steatohepatitis. Semin Liver Dis 2009;29:200-10.
4. Xu R, Tao A, Zhang S, Deng Y, Chen G. Association between patatin-like phospholipase domain containing 3 gene (PNPLA3) polymorphisms and nonalcoholic fatty liver disease: a huge review and meta-analysis. Sci Rep 2015;5:9284. http://dx.doi.org/10.1038/srep09284.
5. Stickel F, Buch S, Lau K, Meyer zu Schwabedissen H, Berg T, Ridinger M, et al. Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. Hepatology 2011;53:86-95. http://dx.doi.org/10.1002/hep.24017.
6. Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013;57:601-9. http://dx.doi.org/10.1002/hep.26093.
7. Nair S, Cope K, Risby TH, Diehl AM, Terence RH. Obesity and female gender increase breath ethanol concentration: potential implications for the pathogenesis of nonalcoholic steatohepatitis. Am J Gastroenterol 2001;96:1200-4. http://dx.doi.org/10.1111/j.1572-0241.2001.03702.x.
8. Buko VU, Kuzmitskaya-Nikolaeva IA, Naruta EE, Lukivskaya OY, Kirko SN, Tauschel H-D. Ursodeoxycholic acid dose-dependently improves liver injury in rats fed a methionine-and choline-deficient diet. Hepatol Res 2011;41:647-59. http://dx.doi.org/10.1111/j.1872-034X.2011.00820.x.
9. Baker SS, Baker RD, Liu W, Nowak NJ, Zhu L. Role of alcohol metabolism in non-alcoholic steatohepatitis. PloS One 2010;5:e9570. http://dx.doi.org/10.1371/journal.pone.0009570.
10. Mezey E, Imbembo AL, Potter JJ, Rent KC, Lombardo R, Holt PR. Endogenous ethanol production and hepatic disease following jejunoileal bypass for morbid obesity. Am J Clin Nutr 1975;28:1277-83.
11. Baraona E, Julkunen R, Tannenbaum L, Lieber CS. Role of intestinal bacterial overgrowth in ethanol production and metabolism in rats. Gastroenterology 1986;90:103-10.
12. Picot D, Lauvin R, Hellegouarc'h R [Intra-digestive fermentation in intestinal malabsorption syndromes: relations with elevated serum activity of gammaglutamyl-transpeptidase]. Gastroenterol Clin Biol 1997;21:562-6.
13. Karahanian E, Quintanilla ME, Tampier L, Rivera-Meza M, Bustamante D, Gonzalez-Lira V, et al. Ethanol as a prodrug: brain metabolism of ethanol mediates its reinforcing effects. Alcohol Clin Exp Res 2011;35:606-12. http://dx.doi.org/10.1111/j.1530-0277.2011.01439.x.
14. Ye Q, Wang X, Wang Q, Xia M, Zhu Y, Lian F, et al. Cytochrome P4502E1 inhibitor, chlormethiazole, decreases lipopolysaccharide-induced inflammation in rat Kupffer cells with ethanol treatment. Hepatol Res 2013;43:1115-23. http://dx.doi.org/10.1111/hepr.12063.
15. Swaminathan K, Clemens DL, Dey A. Inhibition of CYP2E1 leads to decreased malondialdehyde-acetaldehyde adduct formation in VL-17A cells under chronic alcohol exposure. Life Sci 2013;92:325-36. http://dx.doi.org/10.1016/j.lfs.2012.12.014.
16. Schaffert CS, Duryee MJ, Bennett RG, Deveney AL, Tuma DJ, Olinga P, et al. Exposure of precision-cut rat liver slices (PCLS) to ethanol accelerates fibrogenesis. Am J Physiol Gastrointest Liver Physiol 2010;299:G661-8. ajpgi.00287.2009 [pii]10.1152/ajpgi.00287.2009 LA-ENG.
17. Mello T, Ceni E, Surrenti C, Galli A. Alcohol induced hepatic fibrosis: role of acetaldehyde. Mol Aspects Med 2008;29:17-21. http://dx.doi.org/10.1016/j.mam.2007.10.001.
18. Aleryani S, Kabakibi A, Cluette-Brown J, Laposata M. Fatty acid ethyl ester synthase, an enzyme for nonoxidative ethanol metabolism, is present in serum after liver and pancreatic injury. Clin Chem 1996;42:24-7.
19. Bhopale KK, Wu H, Boor PJ, Popov VL, Ansari GAS, Kaphalia BS. Metabolic basis of ethanol-induced hepatic and pancreatic injury in hepatic alcohol dehydrogenase deficient deer mice. Alcohol 2006;39:179-88. http://dx.doi.org/10.1016/j.alcohol.2006.09.005.
20. Matysiak-Budnik T, Jokelainen K, Kärkkäinen P, Mäkisalo H, Ohisalo J, Salaspuro M. Hepatotoxicity and absorption of extrahepatic acetaldehyde in rats. J Pathol 1996;178:469-74. http://dx.doi.org/10.1002/(SICI)1096-9896(199604)178:4<469::AID-PATH510>3.0.CO;2-9.
21. Bankowski E, Pawlicka E, Sobolewski K. Liver collagen of rats submitted to chronic intoxication with acetaldehyde. Mol Cell Biochem 1993;121:37-43.
22. Barry RE, McGivan JD. Acetaldehyde alone may initiate hepatocellular damage in acute alcoholic liver disease. Gut 1985;26:1065-9.
23. Jones AW, Mårdh G, Anggård E. Determination of endogenous ethanol in blood and breath by gas chromatography-mass spectrometry. Pharmacol Biochem Behav 1983;18(Suppl 1):267-72.
24. Turner C, Spanel P, Smith D. A longitudinal study of ethanol and acetaldehyde in the exhaled breath of healthy volunteers using selected-ion flow-tube mass spectrometry. Rapid Commun Mass Spectrom 2006;20:61-8. http://dx.doi.org/10.1002/rcm.2275.
25. Krebs HA, Perkins JRC-P. The physiological role of liver alcohol dehydrogenase. Biochem J 1970;118:635-44.
26. Cope K, Risby T, Diehl AM. Increased gastrointestinal ethanol production in obese mice. implications for fatty liver disease pathogenesis. Gastroenterology 2000;119:1340-7.
27. Menezes CN, Raal F, Immelman A, Song E. The role of increased gastrointestinal alcohol production in patients with the metabolic syndrome: Implications for the pathogenesis of non-alcoholic fatty liver disease. J Endocrinol Metab Diabetes South Africa 2008;13:48-56.
28. Klipstein FA, Engert RF. Enterotoxigenic intestinal bacteria in tropical sprue. III. Preliminary characterization of Klebsiella pneumoniae enterotoxin. J Infect Dis 1975;132:200-3.
29. Halsted CH, Robles EA, Mezey E. Distribution of ethanol in the human gastrointestinal tract. Am J Clin Nutr 1973;26:831-4.
30. Zhang Y, Baker SS, Baker RD, Zhu R, Zhu L. Systematic analysis of the gene expression in the livers of nonalcoholic steatohepatitis: implications on potential biomarkers and molecular pathological mechanism. PLoS One 2012;7:e51131. http://dx.doi.org/10.1371/journal.pone.0051131.
31. Cederbaum AI. Alcohol metabolism. Clin Liver Dis 2012;16:667-85. http://dx.doi.org/10.1016/j.cld.2012.08.002.
32. Brick J. Standardization of alcohol calculations in research. Alcohol Clin Exp Res 2006;30:1276-87. http://dx.doi.org/10.1111/j.1530-0277.2006.00155.x.
33. Lindros KO, Stowell L, Väänänen H, Sipponen P, Lamminsivu U, Pikkarainen P, et al. Uninterrupted prolonged ethanol oxidation as a main pathogenetic factor of alcoholic liver damage: evidence from a new liquid diet animal model. Liver 1983;3:79-91.
34. Kovach SJ, Sitzmann JV, McKillop IH. Inhibition of alcohol dehydrogenase blocks enhanced Gi-protein expression following ethanol treatment in experimental hepatocellular carcinoma in vitro. Eur J Gastroenterol Hepatol 2001;13:1209-16.
35. Dolai S, Liang T, Lam PP, Fernandez NA, Chidambaram S, Gaisano HY. Effects of ethanol metabolites on exocytosis of pancreatic acinar cells in rats. Gastroenterology 2012;143:832-43. http://dx.doi.org/10.1053/j.gastro.2012.06.011.
36. Kahn EDF. Anatomy, histology, embryology, and developmental anomalies of the small and large intestine. In: Feldman M, Friedman LS, Brandt L, editors. Sleisenger Fordtran's Gastrointest. Liver Dis.-2 vol. set. 9th ed. Philadelphia, PA: Saunders Elsevier; 2010, p. 1615-40.
37. Burkitt D. Fiber Deficiency and colonic tumors. In: Reilly RW, KJ, editor. Fiber Defic. Colon. Disord. 1st ed., Springer, US-Plenum Publishing Corporation; 1975, p. 139-47. http://dx.doi.org/10.1007/978-1-4684-2172-9_11.
38. Sabate JM, Jouet P, Harnois F, Mechler C, Msika S, Grossin M, et al. High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis. Obes Surg 2008;18:371-7.
39. Shanab AA, Scully P, Crosbie O, Buckley M, O'Mahony L, Shanahan F, et al. Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with toll-like receptor 4 expression and plasma levels of interleukin 8. Dig Dis Sci 2011;56:1524-34. http://dx.doi.org/10.1007/s10620-010-1447-3.
40. Giorgio V, Miele L, Principessa L, Ferretti F, Villa MP, Negro V, et al. Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity. Dig Liver Dis 2014;46:556-60. http://dx.doi.org/10.1016/j.dld.2014.02.010.
41. Jin X, Yu CH, Lv GC, Li YM. Increased intestinal permeability in pathogenesis and progress of nonalcoholic steatohepatitis in rats. World J Gastroenterol 2007;13:1732-6.
42. Brun P, Castagliuolo I, Leo VD, Buda A, Pinzani M, Palu G, et al. Increased intestinal permeability in obese mice. new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2007;292:G518-25.
43. Vanderhoof JA, Tuma DJ, Antonson DL, Sorrell MF. Effect of antibiotics in the prevention of jejunoileal bypass-induced liver dysfunction. Digestion 1982;23:9-15.
44. Lichtman SN, Keku J, Schwab JH, Sartor RB. Hepatic injury associated with small bowel bacterial overgrowth in rats is prevented by metronidazole and tetracycline. Gastroenterology 1991;100:513-9.
45. Bergheim I, Weber S, Vos M, Krämer S, Volynets V, Kaserouni S, et al. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice. role of endotoxin. J Hepatol 2008;48:983-92. http://dx.doi.org/10.1016/j.jhep.2008.01.035.
46. Membrez M, Blancher F, Jaquet M, Bibiloni R, Cani PD, Burcelin RG, et al. Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. Faseb J 2008;22:2416-26.
47. Adachi Y, Moore LE, Bradford BU, Gao W, Thurman RG. Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology 1995;108:218-24.
48. Backhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A 2007;104:979-84.
49. Le Roy T, Llopis M, Lepage P, Bruneau A, Rabot S, Bevilacqua C, et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 2013;62:1787-94. http://dx.doi.org/10.1136/gutjnl-2012-303816.
50. Lichtman SN, Sartor RB, Keku J, Schwab JH. Hepatic inflammation in rats with experimental small intestinal bacterial overgrowth. Gastroenterology 1990;98:414-23.
51. Alkhouri N, Cikach F, Eng K, Moses J, Patel N, Yan C, et al. Analysis of breath volatile organic compounds as a noninvasive tool to diagnose nonalcoholic fatty liver disease in children. Eur J Gastroenterol Hepatol 2014;26:82-7. http://dx.doi.org/10.1097/MEG.0b013-3283650669
52. Dahshan A, Donovan K. Auto-brewery syndrome in a child with short gut syndrome: case report and review of the literature. J Pediatr Gastroenterol Nutr 2001;33:214-5.
53. Nosova T, Jousimies-Somer H, Kaihovaara P, Jokelainen K, Heine R, Salaspuro M. Characteristics of alcohol dehydrogenases of certain aerobic bacteria representing human colonic flora. Alcohol Clin Exp Res 1997;21:489-94.
54. O'Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Am J Gastroenterol 2010;105:14-32. http://dx.doi.org/10.1038/ajg.2009.593.
55. Klyosov AA, Rashkovetsky LG, Tahir MK, Keung WM. Possible role of liver cytosolic and mitochondrial aldehyde dehydrogenases in acetaldehyde metabolism. Biochemistry 1996;35:4445-56. http://dx.doi.org/10.1021/bi9521093.
56. Jokelainen K, Parkkila S, Salaspuro M, Niemelä O. Covalent adducts of proteins with acetaldehyde in the liver as a result of acetaldehyde administration in drinking water. J Hepatol 2000;33:926-32.
57. Nuutinen H, Lindros KO, Salaspuro M. Determinants of blood acetaldehyde level during ethanol oxidation in chronic alcoholics. Alcohol Clin Exp Res 1983;7:163-8.
58. Thomas M, Halsall S, Peters TJ. Role of hepatic acetaldehyde dehydrogenase in alcoholism: demonstration of persistent reduction of cytosolic activity in abstaining patients. Lancet 1982;2:1057-8.
59. Alderman JA, Sanny C, Gordon E, Lieber CS. Ethanol feeding can produce secondary alterations in aldehyde dehydrogenase isozymes. Alcohol 1985;2:91-5.
60. Rolla R, Vay D, Mottaran E, Parodi M, Traverso N, Aricó S, et al. Detection of circulating antibodies against malondialdehyde-acetaldehyde adducts in patients with alcohol-induced liver disease. Hepatology 2000;31:878-84. http://dx.doi.org/10.1053/he.2000.5373.S0270913900170168[pii].
61. Vehkala L, Ukkola O, Kesäniemi YA, Kähönen M, Nieminen MS, Salomaa V, et al. Plasma IgA antibody levels to malondialdehyde acetaldehyde-adducts are associated with inflammatory mediators, obesity and type 2 diabetes. Ann Med 2013;45:501-10. http://dx.doi.org/10.3109/07853890.2013.841322.
62. Viitala K, Israel Y, Blake JE, Niemela O. Serum IgA, IgG, and IgM antibodies directed against acetaldehyde-derived epitopes: relationship to liver disease severity and alcohol consumption. Hepatology 1997;25:1418-24.
63. Setshedi M, Wands JR, de la Monte SM. Acetaldehyde adducts in alcoholic liver disease. Oxidative Med Cell Longevity 2010;3:178-85. http://dx.doi.org/10.4161/oxim.3.3.12288.
64. Chen C-H, Ferreira JCB, Gross ER, Mochly-Rosen D. Targeting aldehyde dehydrogenase 2: new therapeutic opportunities. Physiol Rev 2014;94:1-34. http://dx.doi.org/10.1152/physrev.00017.2013.
65. Song B-J, Abdelmegeed MA, Yoo S-H, Kim B-J, Jo SA, Jo I, et al. Posttranslational modifications of mitochondrial aldehyde dehydrogenase and biomedical implications. J Proteomics 2011;74:2691-702. http://dx.doi.org/10.1016/j.jprot.2011.05.013.
66. Eriksson CJP. Genetic-epidemiological evidence for the role of acetaldehyde in cancers related to alcohol drinking. Adv Exp Med Biol 2015;815:41-58. http://dx.doi.org/10.1007/978-3-319-09614-8_3.
67. White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 2012;10(1342-59):e2. http://dx.doi.org/10.1016/j.cgh.2012.10.001.
68. Dobbins M, Decorby K, Choi BCK. The association between obesity and cancer risk: a meta-analysis of observational studies from 1985 to 2011. ISRN Prev Med 2013;2013:680536. http://dx.doi.org/10.5402/2013/680536.
69. Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care 2012;35:2402-11. http://dx.doi.org/10.2337/dc12-0336.
70. Noto H, Tsujimoto T, Noda M. Significantly increased risk of cancer in diabetes mellitus patients: a meta-analysis of epidemiological evidence in Asians and non-Asians. J Diabetes Investig 2012;3:24-33. http://dx.doi.org/10.1111/j.2040-1124.2011.00183.x.
71. Minville C, Hilleret M-N, Tamisier R, Aron-Wisnewsky J, Clement K, Trocme C, et al. Nonalcoholic fatty liver disease, nocturnal hypoxia, and endothelial function in patients with sleep apnea. Chest 2014;145:525-33. http://dx.doi.org/10.1378/chest.13-0938.
72. Sookoian S, Pirola CJ. Obstructive sleep apnea is associated with fatty liver and abnormal liver enzymes: a meta-analysis. Obes Surg 2013;23:1815-25. http://dx.doi.org/10.1007/s11695-013-0981-4.
73. Lee O, Bruce WR, Dong Q, Bruce J, Mehta R, O'Brien PJ. Fructose and carbonyl metabolites as endogenous toxins. Chem Biol Interact 2009;178:332-9.
74. Yang K, Feng C, Lip H, Bruce WR, O'Brien PJ. Cytotoxic molecular mechanisms and cytoprotection by enzymic metabolism or autoxidation for glyceraldehyde, hydroxypyruvate and glycolaldehyde. Chem Biol Interact 2011;191:315-21. http://dx.doi.org/10.1016/j.cbi.2011.02.027.
75. Shangari N, Chan TS, Popovic M, O'Brien PJ. Glyoxal markedly compromises hepatocyte resistance to hydrogen peroxide. Biochem Pharmacol 2006;71:1610-8.
76. Shangari N, Bruce WR, Poon R, O'Brien PJ. Toxicity of glyoxals-role of oxidative stress, metabolic detoxification and thiamine deficiency. Biochem Soc Trans 2003;31:1390-3.
77. Kimura Y, Hyogo H, Yamagishi S, Takeuchi M, Ishitobi T, Nabeshima Y, et al. Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol 2010;45:750-7. http://dx.doi.org/10.1007/s00535-010-0203-y.
78. MacDonald GA, Bridle KR, Ward PJ, Walker NI, Houglum K, George DK, et al. Lipid peroxidation in hepatic steatosis in humans is associated with hepatic fibrosis and occurs predominately in acinar zone 3. J Gastroenterol Hepatol 2001;16:599-606. jgh2445 [pii].
79. George J, Pera N, Phung N, Leclercq I, Yun Hou J, Farrell G. Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J Hepatol 2003;39:756-64.
80. Albano E, Mottaran E, Vidali M, Reale E, Saksena S, Occhino G, et al. Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut 2005;54:987-93.
81. Ruiz AG, Casafont F, Crespo J, Cayón A, Mayorga M, Estebanez A, et al. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes Surg 2007;17:1374-80. http://dx.doi.org/10.1007/s11695-007-9243-7.
82. Erridge C. Diet, commensals and the intestine as sources of pathogenassociated molecular patterns in atherosclerosis, type 2 diabetes and nonalcoholic fatty liver disease. Atherosclerosis 2011;216:1-6. http://dx.doi.org/10.1016/j.atherosclerosis.2011.02.043.
83. Wu H, Cai P, Clemens DL, Jerrells TR, Ansari GA, Kaphalia BS. Metabolic basis of ethanol-induced cytotoxicity in recombinant HepG2 cells: role of nonoxidative metabolism. Toxicol Appl Pharmacol 2006;216:238-47. http://dx.doi.org/10.1016/j.taap.2006.05.003.S0041-008X(06)00157-8[pii].
84. Aydin HH, Celik HA, Deveci R, Karacali S, Saydam G, Bedii Omay S, et al. Induction of apoptosis by fatty acid ethyl esters in HepG2 cells. Food Chem Toxicol 2005;43:139-45. http://dx.doi.org/10.1016/j.fct.2004.09.003.S0278-6915(04)00285-6[pii].
85. Lu K, Gul H, Upton PB, Moeller BC, Swenberg JAC. Formation of hydroxymethyl DNA adducts in rats orally exposed to stable isotope labeled methanol. Toxicol Sci 2012;126:28-38. http://dx.doi.org/10.1093/toxsci/kfr328.
86. MacAllister SL, Choi J, Dedina L, O'Brien PJ. Metabolic mechanisms of methanol/formaldehyde in isolated rat hepatocytes: carbonyl-metabolizing enzymes versus oxidative stress. Chem Biol Interact 2011;191:308-14. http://dx.doi.org/10.1016/j.cbi.2011.01.017.
87. Jorgacevic B, Mladenovic D, Ninkovic M, Prokic V, Stankovic M, Aleksic V, et al. Dynamics of oxidative/nitrosative stress in mice with methionine-cholinedeficient diet-induced nonalcoholic fatty liver disease. Hum Exp Toxicol 2013;33:701-9. http://dx.doi.org/10.1177/0960327113506723.
88. Musso G, Gambino R, De Michieli F, Biroli G, Premoli A, Pagano G, et al. Nitrosative stress predicts the presence and severity of nonalcoholic fatty liver at different stages of the development of insulin resistance and metabolic syndrome: possible role of vitamin A intake. Am J Clin Nutr 2007;86:661-71. doi:86/3/661 [pii].